OncoGenex Pharma (OGXI) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016
August 4, 2016 4:01 PM EDTBOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 4, 2016 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its second quarter 2016 financial results and provided a summary of anticipated milestones.
Financial Results and Anticipated Near-term Milestones
As of June 30, 2016, the company's cash, cash equivalents, and short-term investments were $39.7 million compared with $55.2 million as of December 31, 2015.
Based on current expectations, OncoGenex believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its currently planned operations into the third quarter of 2017. Depending on timing of enrollment or... More
